GSK backs full-year view as Q1 sales slip, but top forecasts

26 Apr 2023
firstwordpharma.com
Phase 3VaccineFinancial Statement
Headline results for the first quarter:
Revenue: £7 billion ($8.7 billion; forecasts of £6.5 billion), down 3%
Profit: £1.5 billion ($1.9 billion; forecasts of £1.2 billion), versus £1.8 billion in the prior year
Note: All changes are versus the prior-year period unless otherwise stated
What the company said:
"We have made a strong start to 2023, with excellent performance across vaccines, specialty and general medicines," remarked CEO Emma Walmsley.
GSK disclosed that a judgment was entered against the company on April 5 in its royalty dispute with AstraZeneca over Zejula, although it is considering an appeal. The court upheld AstraZeneca’s interpretation that all current uses of Zejula generate royalty-bearing sales under the wording of two license agreements. As such, GSK will owe past royalties to AstraZeneca, which will be determined at a later date, as well as going forward.
Other results:
Speciality medicines: £2.2 billion, down 29%
HIV product sales: £1.5 billion, up 24%
Dovato: £396 million, up 54%
Triumeq: £374 million, down 5%
Tivicay: £357 million, up 12%
Cabenuva: £127 million, up >100%
Oncology product sales: £136 million, up 7%
Zejula: £114 million, up 16%
Nucala: £347 million, up 18%
Benlysta: £253 million, up 18%
Xevudy: £31 million, down 98%
General medicines: £2.7 billion, up 12%
Respiratory: £1.8 billion, up 15%
Trelegy Ellipta: £465 million, up 37%
Seretide/Advair: £339 million, up 12%
Relvar/Breo Ellipta: £274 million, flat versus the prior year
Vaccine sales: £2 billion, up 22%
Shingrix: £833 million, up 19%
Bexsero: £218 million, up 34%
Menveo: £59 million, up 40%
Looking ahead:
GSK reiterated that it expects sales this year to increase between 6% and 8% at constant currencies, with operating profit growing in the range of 10% to 12%.
What analysts said:
Citi analyst Andrew Baum noted that even after stripping out one-time contributions, GSK's underlying revenue and earnings beat were a respectable 3% and 4%, respectively, in the quarter.
Pipeline updates:
GSK said that earlier this month it ended enrolment in the Phase III ZEST study investigating the PARP inhibitorPARP inhibitor Zejula in patients with either HER2-negative BRCA-mutated or triple-negative breast cancer with molecular disease based on the presence of circulating tumour DNA (ctDNA) after definitive therapy. The company explained that recruitment for the trial was "much more challenging" than initially thought as the prevalence of radiologically detectable metastatic disease among patients who are ctDNA positive is much higher than expected. This enabled patients to be referred for treatment of metastatic cancer ahead of clinical symptoms, making patients ineligible for ZEST.
($1 = £0.801407)
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.